Amlitelimab, an OX40-OX40L pathway inhibitor, has been shown to reduce serum levels of IL-22, IL-13, and IL-31, offering a potential treatment option for AD patients with dominant Th2/Th22-driven inflammation (45). This evidence concerns the gene TNFRSF4 and Alzheimer disease.